Walleye Capital
HOWL icon

Walleye Capital’s Werewolf Therapeutics HOWL Stock Holding History

Walleye Capital’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-59,347
Closed -$57.7K – 4707
2025
Q1 		$57.7K Sell
59,347
-37,503
-39% -$49.1K ﹤0.01% 3806
2024
Q4 		$143K Sell
96,850
-12,118
-11% -$24.7K ﹤0.01% 3952
2024
Q3 		$231K Buy
108,968
+10,528
+11% +$23.9K ﹤0.01% 3891
2024
Q2 		$240K Buy
+98,440
New +$473K ﹤0.01% 4165

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Walleye Capital's HOWL Position: Q2 2025 in Review

Walleye Capital sold out of Werewolf Therapeutics (HOWL) in Q2 2025, closing a stake of 59,347 shares — an estimated $57.7K sold.

Walleye Capital first reported a position in HOWL in Q2 2024 and held it in 4 quarters. The position peaked at $240K in Q2 2024. 65 funds tracked by Wall St. Rank hold HOWL as of Q2 2025.

  • Walleye Capital reported no remaining Werewolf Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 59,347 Werewolf Therapeutics shares in Q2 2025, an estimated $57.7K.
  • Walleye Capital first reported a position in Werewolf Therapeutics in Q2 2024 and held it in 4 quarters.
  • Walleye Capital's Werewolf Therapeutics position peaked at $240K in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.